Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) Receives Consensus Rating of "Buy" from Analysts

Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report) has earned an average rating of "Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the company.

RBGLY has been the subject of several recent analyst reports. Royal Bank Of Canada restated an "outperform" rating on shares of Reckitt Benckiser Group in a research report on Friday, March 7th. Sanford C. Bernstein upgraded Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th.

Reckitt Benckiser Group Stock Down 0.7%

Shares of OTCMKTS:RBGLY traded down $0.10 during midday trading on Wednesday, reaching $13.63. 278,173 shares of the company traded hands, compared to its average volume of 311,293. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.39 and a current ratio of 0.58. Reckitt Benckiser Group has a 12 month low of $10.43 and a 12 month high of $14.15. The firm's fifty day moving average price is $13.38 and its two-hundred day moving average price is $13.04.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.